nach oben

Erschienen in:

06.02.2024 | Prostatakarzinom | Zertifizierte Fortbildung

Möglichkeiten und Limitationen der Detektionsmethode

PSMA-PET/CT beim Prostatakarzinom*

verfasst von: PD Dr. med. Felix Preisser, apl. Prof. Dr. med. Wolfgang P. Fendler, Prof. Dr. med. Derya Tilki

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 1-2/2024

zum CME-Kurs Einloggen, um Zugang zu erhalten

Auszug

Die Positronenemissionscomputertomografie des prostataspezifischen Membran-Antigens hat die Diagnostik des Prostatakarzinoms in den letzten Jahren nahezu revolutioniert. Im Vergleich zu den konventionellen Bildgebungen ist die Genauigkeit der PSMA-PET/CT deutlich höher, was eine frühere Detektion von Metastasen ermöglicht. Wie groß ist der Vorteil bei der onkologischen Tumorkontrolle? …

Hupe MC et al. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis. Front Oncol. 2018;8:623

Hofman MS et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-16

Evangelista L et al. [68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. Eur Urol Oncol. 2022;5(3): 273-82

Giesel FL et al. Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. J Nucl Med Off Publ Soc Nucl Med. 2018;59(7):1076-80

Kuten J et al. Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard. J Nucl Med Off Publ Soc Nucl Med. 2020;61(4):527-32

https://uroweb.org/guideline/prostate-cancer abgerufen am 13. Dezember 2023

www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom abgerufen am 13. Dezember 2023

Maurer T et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol. 2016;195(5):1436-43

Pyka T et al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(12):2114-21

10.

Franklin A et al. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU Int. 2021;127(1):71-9

11.

Perera M et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer - Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77(4):403-17

12.

Esen T et al. 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy. Eur Urol Focus. 2021;7(2):288-93

13.

Budäus L et al. Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol. 2016;69(3):393-6

14.

Fendler WP et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019;5(6):856-63

15.

Roach PJ et al. The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med Off Publ Soc Nucl Med. 2018;59(1):82-8

16.

Sonni I et al. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. J Nucl Med Off Publ Soc Nucl Med. 2020;61(8):1153-60

17.

Han S et al. Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2018;74(2):179-90

18.

Golan S et al. Neoadjuvant 177Lu-PSMA-I&T Radionuclide Treatment in Patients with High-risk Prostate Cancer Before Radical Prostatectomy: A Single-arm Phase 1 Trial. Eur Urol Oncol 2023;6(2):151-9

19.

Maurer T et al. 99mTechnetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate Cancer. Eur Urol. 2019;75(4):659-66

20.

de Barros HA et al. Robot-assisted Prostate-specific Membrane Antigen-radioguided Salvage Surgery in Recurrent Prostate Cancer Using a DROP-IN Gamma Probe: The First Prospective Feasibility Study. Eur Urol. 2022;82(1):97-105

21.

Knipper S et al. Metastases-yield and Prostate-specific Antigen Kinetics Following Salvage Lymph Node Dissection for Prostate Cancer: A Comparison Between Conventional Surgical Approach and Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol Focus. 2019;5(1):50-3

22.

Knipper S et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol. 2023;83(1):62-9

23.

Gandaglia G et al. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study. Eur Urol. 2022;82(4):411-8

24.

Gondoputro W et al. Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer. J Nucl Med Off Publ Soc Nucl Med. 2022;63(11):1659-64

25.

Tilki D et al. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol 2023;41(13):2428-35

Titel: Möglichkeiten und Limitationen der Detektionsmethode
PSMA-PET/CT beim Prostatakarzinom*
verfasst von: PD Dr. med. Felix Preisser
apl. Prof. Dr. med. Wolfgang P. Fendler
Prof. Dr. med. Derya Tilki
Publikationsdatum: 06.02.2024
Verlag: Springer Medizin
Schlagwörter: Prostatakarzinom
Prostatakarzinom
Positronen-Emissions-Tomografie
Computertomografie
Computertomografie
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe 1-2/2024
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-023-0455-3

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1-2/2024

Klonale Hämatopoese: Risikoscore zur Prognoseabschätzung?

Neues Antikörper-Wirkstoff-Konjugat

Vierfach-Antiemese: Low-dose-Olanzapin scheint nicht unterlegen

Vernetzung von Industrie und Akademie

Radiotherapie plus Nivolumab beim NSCLC

Langzeitdaten zu Ibrutinib/Venetoclax